[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-353728-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-353728-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","the-impact-of-p53-mutation-on-tumor-immune-evasion-mechanistic-insights-and-clinical-implications","The impact of p53 mutation on tumor immune evasion: mechanistic insights and clinical implications","","Mutant p53 (Mtp53) loses tumor-suppressive functions while gaining oncogenic activities that reshape the tumor immune microenvironment. This review details how Mtp53 forms and sustains an immunosuppressive niche through linked pathways including chronic inflammation, immune-cell dysfunction, stromal fibroblast reprogramming, metabolic dysregulation, epigenetic hijacking, and possible liquid–liquid phase separation. Evidence supports a “metabolism–epigenetics–immunity” axis, but a complete in vivo causal chain remains unresolved and effects vary by context and tissue origin. Therapeutic options span reactivators, degraders, synthetic lethality, and neoantigen vaccines, with biomarker-guided combinations needed.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/the-impact-of-p53-mutation-on-tumor-immune-evasion-mechanistic-insights-and-clinical-implications/353728/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/the-impact-of-p53-mutation-on-tumor-immune-evasion-mechanistic-insights-and-clinical-implications/353728.png","ImageObject",300,407,{"name":42,"@type":43},"Levi","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"How does mutant p53 influence the tumor immune microenvironment?","Question",{"text":63,"@type":64},"Mutant p53 reshapes the tumor immune microenvironment by establishing and sustaining an immunosuppressive niche. The review links this effect to mechanisms such as chronic inflammation, immune-cell dysfunction, fibroblast reprogramming, metabolic dysregulation, and epigenetic hijacking.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What is the proposed “metabolism–epigenetics–immunity” axis?",{"text":68,"@type":64},"The review proposes that Mtp53-driven metabolic reprogramming (e.g., lactate or a-ketoglutarate accumulation) can modulate chromatin modifications and immune gene expression. While supported by stepwise experimental evidence and correlations, the full in vivo causal chain has not been fully established.",{"name":70,"@type":61,"acceptedAnswer":71},"Why do mutant p53 effects on immunotherapy differ across cancers?",{"text":72,"@type":64},"The immunological impact of Mtp53 is highly context-dependent, influenced by comutations and tissue origin. In some settings like TP53/KRAS co-mutant NSCLC, Mtp53 may enhance immunogenicity and improve response to ICIs, whereas in immunologically “cold” tumors it may drive T-cell exhaustion or myeloid suppression, reflecting cancer-type heterogeneity.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},353728,1790196471,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},7971461740909,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","TYPE Review  \nPUBLISHED 06 February 2026 DOI 10.3389/fimmu.2026.1753215  \nOPEN ACCESS  \nEDITED BY  \nZebo Jiang,  \nZhuhai Hospital of Integrated Traditional Chinese & Western Medicine, China  \nREVIEWED BY  \nShu Liu,  \nChanghai Hospital, China Chen Qianqian,  \nHefei Comprehensive National Science Center, China  \n*CORRESPONDENCE  \nWeidong Wang  \n[wwdwyl@sina.com](wwdwyl@sina.com)  \nRECEIVED 24 November 2025  \nREVISED 14 January 2026  \nACCEPTED 20 January 2026  \nPUBLISHED 06 February 2026  \nCITATION  \nLiang L and Wang W (2026) The impact of p53 mutation on tumor immune evasion:  \nmechanistic insights and clinical implications. Front. Immunol. 17:1753215 .  \ndoi: 10.3389/fimmu.2026.1753215  \nCOPYRIGHT  \n© 2026 Liang and Wang. This is an openaccess article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nThe impact of p53 mutation on tumor immune evasion:  \nmechanistic insights and clinical implications  \nLuo Liang 1 and Weidong Wang 2*  \n1 Department of Radiation Oncology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, 2 Department of Head and Neck Radiation Oncology, Radiation Oncology Key Laboratory of Sichuan Province, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China  \nMutant p53(Mtp53) not only loses its canonical tumor-suppressive functions but also acquires oncogenic gain-of-function properties, positioning it as a central orchestrator in reshaping the tumor immune microenvironment. This review systematically delineates how Mtp53 actively establishes and sustains an immunosuppressive niche through multiple interconnected mechanisms, including chronic inﬂammation, immune cell dysfunction, reprogramming of cancer-associated ﬁbroblasts, metabolic dysregulation, epigenetic hijacking, and potentially aberrant liquid–liquid phase separation, thereby promoting immune evasion and therapeutic resistance. We integrate current evidence to propose a conceptual “metabolism–epigenetics–immunity” axis: Mtp53-driven metabolic reprogramming—such as accumulation of lactate or a-ketoglutarate—can modulate chromatin modiﬁcations and immune gene expression. Notably, the full in vivo causal chain of this axis remains unestablished; existing support derives primarily from stepwise experimental data and strong correlations. The immunological impact of Mtp53 is highly context-dependent, shaped by comutations and tissue origin. In TP53/KRAS co-mutant non-small cell lung cancer (NSCLC), Mtp53 enhances tumor immunogenicity and improves response to immune checkpoint inhibitors (ICIs); conversely, in immunologically“cold” tumors—such as triple-negative breast cancer, pancreatic ductaladenocarcinoma, and colorectal cancer—it promotes T-cell exhaustion or myeloid suppression, reﬂecting marked cancer-type heterogeneity. Therapeutic approaches include Mtp53 reactivators (e.g., APR-246, PC14586), degraders, synthetic lethal strategies, and neoantigen vaccines. Although APR- 246 showed efﬁcacy in a phase II trial (NCT03072043), it failed to improve survival in phase III (NCT03745716) due to lack of TP53 mutation stratiﬁcation. Its combination with pembrolizumab (NCT04383938) demonstrated acceptable safety (immune-related adverse events in ∼12%) but limited efﬁcacy, underscoring the need for biomarker-guided, precision-based combinations. Thus, a multidimensional biomarker platform is urgently needed—one  \nFrontiers i","cbCaij6RNacsn10N","https://ap.wps.com/l/cbCaij6RNacsn10N","pdf",4025467,33,"English","# Introduction\n## The tumor immune microenvironment and immunotherapy response\n# Mutant p53 and mechanisms of immune evasion\n## Metabolism–epigenetics–immunity axis\n## Therapeutic strategies and biomarker needs","[{\"question\":\"How does mutant p53 influence the tumor immune microenvironment?\",\"answer\":\"Mutant p53 reshapes the tumor immune microenvironment by establishing and sustaining an immunosuppressive niche. The review links this effect to mechanisms such as chronic inflammation, immune-cell dysfunction, fibroblast reprogramming, metabolic dysregulation, and epigenetic hijacking.\"},{\"question\":\"What is the proposed “metabolism–epigenetics–immunity” axis?\",\"answer\":\"The review proposes that Mtp53-driven metabolic reprogramming (e.g., lactate or a-ketoglutarate accumulation) can modulate chromatin modifications and immune gene expression. While supported by stepwise experimental evidence and correlations, the full in vivo causal chain has not been fully established.\"},{\"question\":\"Why do mutant p53 effects on immunotherapy differ across cancers?\",\"answer\":\"The immunological impact of Mtp53 is highly context-dependent, influenced by comutations and tissue origin. In some settings like TP53/KRAS co-mutant NSCLC, Mtp53 may enhance immunogenicity and improve response to ICIs, whereas in immunologically “cold” tumors it may drive T-cell exhaustion or myeloid suppression, reflecting cancer-type heterogeneity.\"}]","The impact of p53 mutation on tumor immune evasion: mechanistic insights and clinical implications | PDF",1790106978,83,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/308b6a4a47f4ac7dcc7086c69acd649e.webp",983,1389,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/30bdfacb6018cc18168e75e2926748ee.webp",982,1388,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/153d2ffb45c0ee5568ef87728f2e7807.webp",981,1386,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fb9a686741bb9e4fe6f86b1820242fd4.webp",980,1385]